{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 96 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'measurements performed within visits 2-7 will', 'be used.\"', 'Rationale for change', 'Updated to specify treatment period.', 'Section to be changed', '8.7', 'Description of change', 'Changed \"Trial Clinical Monitor\" to', 'Clinical Trial Leader\"', 'Changed \"Local Clinical Monitor', '(CML)\" to Clinical Trial Manager', '(CTM)\"', 'Rationale for change', 'Administrative', 'Section to be changed', '10.1', 'Description of change', 'Changed: \"To supplement the information on', 'the Six Minute Walk Test described in this', 'section, a Manual of procedures and', 'instructional video has been developed. More', 'detailed information on the procedure, on', 'staffing, site and equipment requirements,', 'patient preparation, IC measurements, and', 'calculations etc. can be found in this Manual,', 'which is filed in the ISF.', 'to', '\"To supplement the information on the Six', 'Minute Walk Test described in this section,', 'instructions and an instructional video has been', 'developed. More detailed information on the', 'procedure, on staffing, site and equipment', 'requirements, patient preparation, IC', 'measurements, and calculations etc. can be', 'found in the instructions, which is filed in the', 'ISF.\"', 'Rationale for change', 'Administrative changes.', 'Section to be changed', '10.1.1', 'Description of change', 'Added colons throughout to format.', 'Rationale for change', 'Administrative change.', 'Section to be changed', '10.1.2', 'Description of change', 'Changed/ removed word \"manual\" to', '\"instructions\" throughout section.', 'Rationale for change', 'Administrative change to be in line with the way', 'supporting documents are named in the ISF.', 'Section to be changed', '10.1.3', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 97 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'Description of change', 'After figure 10.1.3:1, main bullet 4 -', 'removed \"d\" prior to the word', '\"dyspnea\".', 'Rationale for change', 'Section to be changed', '10.3', 'Description of change', \"The ST. GEORGE'S RESPIRATORY\", 'QUESTIONNAIRE (SGRQ) was updated to', 'reflect the most current version.', 'Rationale for change', 'Administrative change.', 'Section to be changed', '10.5', 'Description of change', \"The King's Brief ILD Questionnaire (K-BILD)\", 'was updated to reflect the most current version.', 'Rationale for change', 'Administrative change.', 'Section to be changed', '10.7', 'Description of change', 'Updated to allow use of historic data as per', 'inclusion criterion 6 and correction of', 'typographical error in visit number.', 'Rationale for change', 'Administrative change.', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 98 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '11.2', 'GLOBAL AMENDMENT 2', 'Date of amendment', '16 Dec 2019', 'EudraCT number', 'Not applicable', 'EU number', 'BI Trial number', '1199-0324', 'BI Investigational Product(s)', 'nintedanib', 'Title of protocol', 'Study of Pulmonary Rehabilitation In', 'Nintedanib Treated Patients with IPF:', 'Improvements in Activity, Exercise Endurance', 'Time, and QoL', 'To be implemented only after approval of the IRB / IEC / Competent Authorities', 'X', 'To be implemented immediately in order to eliminate hazard -', 'IRB / IEC / Competent Authority to be notified of change with request for', 'approval', 'Can be implemented without IRB / IEC / Competent Authority approval as', 'changes involve logistical or administrative aspects only', 'Section to be changed', 'Title Page', 'Description of change', 'Updated the following:', 'Version', 'Date of Protocol', 'Status', 'Rationale for change', 'Administrative changes', 'Section to be changed', 'Clinical Trial Protocol Synopsis', 'Description of change', 'Updated the following:', 'Revision Date', 'Changed Inclusion Criteria from \"On', 'stable dose of nintedanib for up to 30', 'months\" to \"Treated on a stable dose of', 'nintedanib for up to 30 months. Patients', 'who have recently started nintedanib 150', 'mg BID and have started by the day of', 'randomization must be on nintedanib', '150 mg BID a minimum of 10 days by', 'the first day of pulmonary', 'rehabilitation.\"', 'Changed Inclusion Criteria Forced Vital', 'Capacity (FVC) from 50% of', 'predicted to > 45% of predicted', 'Changed Exclusion Criteria from', '\"Participation in a pulmonary', 'rehabilitation program completed in the', 'past 3 months\" to \"Previous', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}